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Cancer immunotherapy has become an effective treatment in the toolbox of 
oncologists. Immunotherapy offers a less toxic alternative to standard cancer treatments 
such as chemotherapy and can have prolonged curative effects to decrease cancer 
recurrence. Today, many drugs and biological agents have been developed that target the 
immune system and elicit an antitumor/cancer response. These agents are known 
collectively as cancer immunotherapies. While immunotherapies have radically improved 
treatment outcomes for many cancer patients, there are drawbacks to using these 
treatments. Immunotherapy treatments have poor clinical responses in patients with tumors 
that lack immunogenicity. Some of the treatments also pose a risk to induce systemic 
toxicity when used at high doses and risks of autoimmunity are essentially inherent. To 
mitigate these shortcomings of immunotherapies, biomaterials can be used as a delivery 
vehicle to alter the pharmacokinetics, biodistribution, and control release of therapeutic 
agents targeting the immune system. This review article outlines the general design 
considerations of various biomaterials and their applications in cancer immunomodulation. 
Many studies show promising results in murine tumor models with potential for translation 
to human disease, but further research – via rigorous clinical trials – is needed to assess the 
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  Immunotherapy has become a promising tool in the arsenal of cancer treatment 
that utilizes the patient’s immune system to elicit robust, long-lasting anticancer responses. 
Since the FDA approval of the use of IFN-α, a cytokine, in 1986 to treat leukemia, cancer 
immunotherapy has made significant progress in the development of effective 
immunomodulatory treatments with promising results in the fight against cancer [1-3]. These 
treatments include checkpoint inhibitors, CAR T-cell therapy, cytokines, cancer vaccines, 
monoclonal antibodies, and other immunomodulators that boost the cancer immune 
response. Several immunomodulatory drugs and agents have been approved by the FDA 
since 1986 (Table 1). Even though these treatments have proven effective, there are 
shortcoming as well [4]. In particular, immunotherapy treatments using cytokines, cancer 
vaccines, and immune checkpoint inhibitors have proven to be less effective in some 
patients. One of the main issues in these non-responsive patients is a lack of 
immunogenicity in tumors. Many immunotherapies elicit a change in key immune cells 
such as dendritic cells (DC) or T-cells; however, tumors with poor immunogenicity, or 
“cold” tumors, lack many of these cells or possess immune cells that oppose activation of 
the immune system. Another issue that arises is the risk of systemic toxicity. Therapies 
such as Interleukin-2 (IL-2) or programmed cell death protein 1 (PD-1) inhibitors can have 
adverse off target effects and become toxic at high doses [5-6]. Due to this toxicity, only 
small doses of the drugs can be used, so treatment must be focused to ensure the maximum 
effectiveness of the drug. Additionally, using immunomodulatory agents can lead to the 
 2 
 
development of an autoimmune response. In the case of cancer vaccines, treatments can be 
ineffective due to a low number of transfections in DCs thus producing a weak anticancer 
immune response.  




Ipilimumab CTLA4 mAb Melanomaa 2011 
Pembrolizumab PD-1 mAb 
Melanomaa, non-small-cell 
lung cancer, Hodgkin 
lymphoma, advanced gastric 
cancer, microsatellite 
instability-high cancer, head 
and neck cancer and 
advanced urothelial bladder 
cancer 
2014 
Nivolumab PD-1 mAb 
Melanomaa, bladder cancer, 
classical Hodgkin lymphoma, 
colorectal cancer, 
hepatocellular cancer, non-
small-cell lung cancer, kidney 
cancer, squamous cell 
carcinoma of the head and 
neck and urothelial cancer 
2014 
Atezolizumab PD-L1 mAb 
Urothelial cancera and non-
small-cell lung cancer 
2016 
Avelumab PD-L1 mAb 
Merkel cell carcinomaa and 
urothelial cancer 
2017 
Durvalumab PD-L1 mAb 
Urothelial cancera and non-
small-cell lung cancer 
2017 
Cytokines for lymphocyte promotion 
Intron A Recombinant IFNα2b 
Hairy cell leukaemiaa, 
melanoma, follicular 





Therapy Type Approved cancers Year of 
first 
approval 
Roferon-A Recombinant IFNα2a 
Hairy cell leukaemiaa, 
chronic myelogenous 
leukaemia and AIDS-related 
Kaposi sarcoma 
1986 
Aldesleukin Recombinant IL-2 




Stimulates TNF, IL-12 
and IFNγ productionb 




Engineered T cell therapies 
Tisagenlecleucel 
CD19-specific CAR T 
cells 
B cell acute lymphocytic 





CD19-specific CAR T 
cells 











Strain of Mycobacterium 
tuberculosis variant bovis 





HSV type 1 designed to 
replicate within tumours 




CD19 and CD3 
bispecific antibody 






Table 1: US Food and Drug Administration (FDA)-approved caner immunotherapies. CAR, chimeric 
antigen receptor; CTLA4, cytotoxic T lymphocyte antigen 4; GM-CSF, granulocyte–macrophage colony-
stimulating factor; HSV, herpes simplex virus; IFN, interferon; IL, interleukin; mAb, monoclonal antibody; 
PAP, prostatic acid phosphatase; PBMC, peripheral blood mononuclear cell; PD-1, programmed cell death 
1; PD-L1, PD-1 ligand 1. aFirst indication to be approved. bIncreases production of cytokines when topically 
applied. Figure adapted from Ref [8]. 
 
 Drug delivery can be broadly categorized into local delivery and systemic delivery 
(Figure 1). In local drug delivery, the delivery system releases drugs or elicits a response 
in the immediate proximity of the material. The most used biomaterials in local drug 
delivery are hydrogels, scaffolds, and microparticles. Hydrogels and scaffolds provide a 
three-dimensional environment for immune cell recruitment and dendritic cell/antigen 
presenting cell (APC) programming using cancer antigens, as well as, spatiotemporal 
control over the release of immunomodulatory drugs at local sites. Microparticles provides 
an injectable platform for local immunotherapy with a targeted delivery system that focuses 
drug release at the local site and controls the release of the drug. On the other hand, drugs 
delivered systemically distribute throughout the body via the circulatory system. Systemic 
drug delivery biomaterials rely on an accumulation of the biomaterial at the tumor site, 
metastatic sites, and/or lymph nodes. These delivery devices typically include 
nanoparticles and drug conjugates. Nanoparticles are widely used in systemic drug delivery 
to deliver cancer vaccines and provide targeted immunomodulatory drug release to key 
immune cells. Nanoparticles help protect the agents and provides a customizable platform 
to suit numerous applications. Drug conjugation provides a simple approach to target 
delivery of immunotherapy drugs as well as modify the drug’s pharmacokinetics by 
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prolonging circulation and reducing clearance by the mononuclear phagocyte system 
(MPS).  
To overcome the shortcomings of immunotherapy, immunomodulatory 
biomaterials can be developed as immunotherapy delivery systems to improve drug safety 
and efficacy[7-9]. The application and design considerations of immunomodulatory 
biomaterials will be discussed to show the validity of these materials to improve 
immunotherapy treatment. Here, we review the various immunomodulatory biomaterials 
that can be applied in cancer immunotherapy – for both local and systemic delivery 
applications. 
 





Local Immunomodulatory Biomaterials 
When immunotherapy drugs are administered systemically, the patient can 
experience systemic toxicity and other off-target side effects. Therefore, researchers started 
to modify the immunotherapy drugs or package them in nanoparticles to increase their 
safety for systemic administration; however, these treatments often lack sufficient 
accumulation of the payload in tumors needed to elicit an antitumor immune response. To 
overcome these issues, researchers are investigating a more local approach to 
immunomodulation. To accomplish this, macroscale drug delivery devices and 
biomaterials have been developed as promising therapeutic avenues. Taking a local 
approach in immunomodulation of the tumor microenvironment (TME) allows for a 
focused administration of the cancer treatment that directly affects the tumor and immune 
cells that infiltrate the tumor. Current local immunomodulation biomaterials offer 
numerous advantages over systemic immunomodulation [10-13]. First, local 
immunomodulatory biomaterials only need low doses of immunomodulatory drugs/agents 
which circumvents the issue of systemic toxicity and other side effects, such as vascular 
leak syndrome and cytokine release syndrome. Local administration lowers the dose of 
drugs necessary due to the proximity to the treatment site and often incorporate a targeting 
mechanism. These targeting mechanisms can promote immune cell recruitment or target 
circulating immune cells (e.g. antibodies conjugated to the payloads within the local 
immunomodulatory biomaterials). In addition to the low dose requirement, local 
biomaterials spatiotemporally control drug release to optimize the immune response. Local 
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immunomodulatory biomaterials can be customized with a variety of chemical, 
mechanical, and physical properties that optimize the drug release profile. Of note, 
important properties that control drug release from local biomaterials include the rate of 
polymer degradation, diffusion mechanism, and affinity between the biomaterial and the 
drug [12].  
Many of the local biomaterials being developed can be classified as either 
hydrogels, scaffolds, or microparticles. Hydrogels and scaffolds provide a 3-dimensional 
(3D) environment that can be loaded with stimulatory factors to aid in the recruitment of 
APCs, such as DCs. After the host’s immune cells infiltrate the mesh network of the 
hydrogel or scaffold, immunomodulatory drugs such as cancer vaccines, anticancer 
antigens, or adjuvants can be presented to the immune cells to prime an antitumor immune 
response that hinders the growth or proliferation of cancer cells. Microparticles offer a 
different approach to administer cancer vaccines or immunotherapy drugs that can 
potentially target specific immune cells that are frequently found at the tumor site or target 
cancerous cells themselves to deliver the payload. Local immunomodulatory biomaterials 
have made significant strides in cancer treatment by changing the immunogenicity of the 
tumor and by equipping the immune system with the materials for a targeted and sustained 
antitumor response.  
 
Hydrogels 
 Hydrogels are injectable biomaterials that can be made from various polymers, 
including natural polymers, synthetic polymers, or a hybrid composite of the two, that cross 
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links to form a 3D network. In comparison to the other local immunomodulatory 
biomaterials, hydrogels have high biocompatibility, biodegradability, and customizability. 
Another quality of note is the hydrophilic properties of hydrogels and their large swelling 
ratio that creates a conducive environment that aids in immune cell maturation and 
proliferation. Hydrogels can be used to hold numerous types of immunomodulatory agents 
depending on the properties of the polymers and the porosity of the hydrogel. Hydrogels 
can also be made responsive to environmental stimuli. Depending on the stimulus, it can 
cause the sol-gel transition of the hydrogel or could impact the drug release mechanism. 
The unique characteristics of hydrogels make them promising materials for drug delivery, 
sparking interest in various research areas, including tissue engineering[20] and cancer 
immunotherapy [13,15-16]. 
Hydrogels: Design Considerations for Effective Drug Delivery 
In designing effective hydrogels for local immunomodulation, one must consider 
multiple parameters that will affect the drug release profile, biocompatibility, and the 
number of biological agents that can be loaded into the matrix. These parameters can 
include the polymer volume fraction in the hydrogel, the polymer type, the diffusion 
coefficient of the matrix, shear rate, and many more factors that can greatly impact the 
effectiveness of treatment [13,15,17-18]. Hydrogels can be used to immobilize numerous 
immunomodulatory agents; however, the size of the agents that can be stored within the 
polymer mesh of the hydrogel is controlled by the size of the meshwork and its porosity 
[15]. The porosity of hydrogels is determined by the distance between neighboring cross-
links between polymers. As the number of cross-links (or the cross-linking density) 
increases within the hydrogel network, the size of the pores decreases, limiting the size of 
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biological agents that can be loaded into the hydrogel and impacting immune cell 
infiltration. Cross-linking density also dictates the shear rate, diffusion coefficient, and 
swelling volume of hydrogels. The shear rate of hydrogels affects the injectability of the 
biomaterial. Generally, the viscosity of the hydrogel solution increases as the weight 
percent of polymer is increased. The diffusional capabilities of hydrogel aids in the ability 
to provide a space for immune cell proliferation as well as a matrix to control the release 
of immunomodulatory agents. The swelling volume dictates the hydrogels ability to swell 
from the interactions between the hydrophilic polymers of the matrix and the aqueous ECM 
thus creating a conducive environment for immune cell infiltration and proliferation. A 
visual representation of the impact cross linking density has on the physical properties of 
the hydrogel can be found in Figure 2. Cross linking density is an important factor that 





Figure 2: Relationship between the cross-linking density and the physical properties of the hydrogel. Two 
visual representations of hydrogel structures with a low cross-linking density (left image) and a high cross-
linking density (right image) are included along with a graphical representation of how the properties of the 
hydrogel change as cross-linking density increases. The properties include the shear modulus (G), 
equilibrium volumetric swelling ratio (Q), diffusivity (D), and mesh size (ξ). Figure adapted from Ref [15].  
 
The chemical properties of hydrogels critically impact clinical application and 
effectiveness[18]. The charge and the hydrophilicity of the polymeric chains in the hydrogel 
affect hydrogel swelling from aqueous solutions such as water and biological interstitial 
fluid. Chemical properties of the hydrogel polymers influence compatibility between the 
biomaterial and the immunomodulatory agents. Chemical interactions, either repulsive or 
attractive, between the polymeric meshwork and the immunomodulatory agents impact the 
diffusional capabilities of the biomaterial. By modifying the chemical and physical 
properties of hydrogels, researchers can create a library of different hydrogels that are 
optimized for local immunomodulatory drug delivery.  
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Hydrogels: Synthetic and Natural Polymers  
 Hydrogels can be created using a variety of polymers categorized as natural-based, 
synthetic-based, or a combination of the two[13, 19-21,58]. Natural polymers have intrinsic 
bioreactive and biocompatible properties that closely mimics the ECM. Natural polymers 
have a high degree of biodegradability and degrade into natural byproducts that are easily 
cleared by the body.  Synthetic polymers typically are nonimmunogenic and often do not 
interact with the cellular environment. To encourage biological interactions, synthetic 
polymers can be conjugated to biological ligands and proteins recognizable by host cells. 
Some synthetic polymers pose a risk of toxicity [76] because of issues of biocompatibility 
or with its degradation products, but many synthetic polymers used in hydrogel 
development are FDA-approved. These features of natural and synthetic polymers should 
be taken into consideration when developing an immunomodulatory hydrogel.  
The choice to use a natural polymer or a synthetic polymer is based on a variety of 
physicochemical, mechanical, and biological parameters and guided by the intended use of 
the biomaterial. For instance, hydrogels made from collagen or gelatin are used widely in 
tissue engineering because of their prominent roles in the native extracellular matrix 
(ECM) [20]. Collagen and gelatin have natural chemical properties that make it highly 
bioreactive and easily transition to a gel; however, these polymers generally form 
hydrogels that are structurally weaker than synthetic alternatives. To overcome limitations 
of hydrogels composed of purely natural or synthetic polymers, hybrid polymers are being 
studied to combine the best features of natural and synthetic polymers. In one study, 
researchers developed a hybrid hydrogel composed of levodopa, a stabilizing agent to slow 
biodegradation, and poly(ε-caprolactone-co-lactide) ester-functionalized hyaluronic acid 
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(HA-PCLA) [22]. Hyaluronic acid (HA) is a natural polysaccharide and component of ECM 
in connective tissue that impacts biological processes such as cell migration and 
proliferation. Alone, hyaluronic acid hydrogels have high batch-to-batch variability, 
rapidly biodegrade (detrimental depending on the application), and are often contaminated 
[21]. By combining HA and PCLA, the researchers were able to create a hydrogel that is 
capable of transitioning to a gel state when the solution reaches body temperature and retain 
the desired properties of HA, mainly its high biocompatibility. These hydrogels were able 
to deliver granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance 
immune cell recruitment to the hydrogel and a nanopolyplex-based DNA vaccine. To test 
the prophylactic capabilities of the hydrogel formulation, mice were first immunized with 
the hydrogel containing GM-CSF and the vaccine followed by an injection of B16/OVA 
melanoma cells a week later. As seen in Figure 3, mice immunized with the hydrogel 
containing both the recruiting cytokine and the vaccine had a significantly lower tumor 
index compared to free administration of the cytokine and vaccine (P < 0.001). Compared 
to hydrogels composed of only PCLA, using hybrid hydrogels composed of HA and PCLA 
significantly lowered the tumor index in the prophylactic study (P < 0.05). Using the hybrid 
hydrogels loaded with GM-CSF and the nanopolyplex-based vaccine elicited a strong 
antitumor response that provided continuous protection in some mice after 4 weeks from 
the melanoma inoculation. Hydrogels composed of only natural or synthetic polymers 
show promise as local immunomodulatory biomaterials; however, hybrid hydrogels offer 
a promising avenue to create novel delivery systems combining positive properties of each 




Figure 3: Prophylactic capability of nanoplex DNA vaccine against murine B16/OVA lung melanoma. 
C57BL/6 mice were inoculated with melanoma cells 1 week after receiving hydrogel-based cancer vaccine 
followed by a booster vaccine on day 14. Mice lungs were collected after 4 weeks and foci were quantified 
under dissecting microscope. Treatment groups from left to right are negative control, OVA-loaded HA-
PCLA, (OVA + GM-CSF)-loaded HA-PCLA, free polyplex, free polyplex + GM-CSF, polyplex-loaded 
PCLA, (polyplex + GM-CSF)-loaded PCLA, polyplex-loaded HA-PCLA, (polyplex + GM-CSF)-loaded 
HA-PCLA. The graph above indicates the tumor index calculated as the average of (lung weights x grade) 
for each group. The error bars in the graph indicates mean ± SD (n = 4). Data were analyzed using Student’s 
t-test (*P < 0.05, **P < 0.01, ***P < 0.001). Figure adapted from Ref [22]. 
 
Hydrogels: Stimuli-Responsive “Smart” Hydrogels  
The customizability of hydrogels allows for hydrogels to be designed to respond to 
various environmental stimuli, including pH, temperature, oxidative stress, and enzymatic 
activity, among other cues [58]. For example, a temperature stimulus can be utilized to 
trigger the sol-gel transition after injection of the hydrogel solution. Once the solution 
reaches body temperature, the solution will become more viscous and swell until it reaches 
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a gel state. This phase change is due to a destabilizing effect on the hydrophobic 
interactions between the polymers and hydrophilic interactions with the surrounding 
extracellular fluid. The thermoresponsive property of hydrogels is affected by the 
concentration of thermoresponsive polymers. In one study, researchers developed a 
thermoresponsive triblock copolymer hydrogel composed of poly(γ-ethyl-L-glutamate) 
(PELG) and poly (ethylene glycol) (PEG) arranged as PELG-b-PEG-b-PELG [23]. The 
required temperature to start the sol-to-gel phase transition decreased as the polymer 
concentration increased from 3 wt% to 6 wt% of the hydrogel solution. Thus, changes as 
simple as the polymer concentration in hydrogel solutions cause changes in the gelling 
process and must be taken into consideration when designing an injectable system. 
Carefully modifying the sol-gel transition allows for the hydrogel to be injected at the target 
site and form the biomimicking matrix to recruit immune cells or deliver 
immunomodulatory agents.  
The pH of the microenvironment can cause certain hydrogels to switch chemical, 
mechanical, and physical properties. These pH responsive hydrogels respond differently to 
pH levels depending on the functional groups associated with the polymer [13,18].  Polymers 
with acidic groups cause hydrogels to swell as pH increases due to the deprotonation of 
acidic R groups. On the other hand, polymers with basic R groups cause hydrogels to swell 
when the pH decreases. Stimuli-responsive hydrogels offer “smart” systems capable of 
responding to their microenvironment and tightly regulating material response based on 






 Scaffolds are 3D polymeric networks with applications in host cell recruitment and 
spatiotemporal drug release. Scaffolds and hydrogels have similar functional properties 
that allow for researchers to interchange between the two platforms. Scaffolds can be used 
in a variety of ways to enhance local immunomodulation. Polymeric scaffolds loaded with 
recruitment factors, such as GM-CSF, can promote immune cell recruitment into the 
scaffold matrix where the immune cells can be exposed to cancer vaccines, antitumor 
antigens, or adjuvants to aid in immune cell maturation. Afterward, those newly 
programmed immune cells can leave the scaffold to aid in an antitumor immune response. 
For example, in an intriguing study Ali et al. developed a macroporous poly-lactide-co-
glycolide (PLG) scaffold loaded with GM-CSF, danger signals (unmethylated cytosine-
phosphate-guanine oligonucleotide, or CpG-ODN), and tumor antigens to recruit and 
reprogram DCs to elicit an antitumor response [24] (Figure 4).  A dendritic cell-activating 
scaffold, based on the technology developed by Ali et al., that contains melanoma cell 
lysates is currently in phase I clinical testing. Scaffolds have also been used to act as a 
delivery system for T-cells programmed in vitro such as CAR-T cell therapies [25]. These 
scaffolds, loaded with CAR-T cells and STING agonists, improve T cell infiltration into 
solid tumors and improve the elimination of malignant tumor cells. Scaffolds are generally 
fabricated ex vivo and then must be implanted at the target site; however, there are some 





Figure 4: Process schematic of Ali et. al. infection-mimicking scaffold design. Stage 1: Recruit naïve 
dendritic cells and APCs using released GM-CSF. Stage 2: The recruited dendritic cells/APCs reside in the 
matrix of the scaffold to be programmed using preloaded cancer antigens. Stage 3: The newly programed 
dendritic cells/APCs leave the scaffold to activate T-cells and initiate an anticancer immune response. 
 
Scaffolds: Injectable vs. Surgical 
Surgery has always been a prominent part of the treatment course for oncology 
patients that has curative results, but surgical procedures are not without risk. Implantable 
scaffolds are often placed either at the tumor resection site to lower the chances of relapse 
or placed subcutaneously near a lymph node to recruit and reprogram immune cells. Many 
of the implantable scaffolds in development are composed of PLG due to its long-standing 
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FDA approval, record of biocompatibility, and material tunability. In one study of note on 
implantable scaffolds, the 3D printed PLGA scaffold developed by Yang et al. acted as a 
drug delivery device for combination chemotherapy using 5-fluorouracil and NVP-
BEZ235, known as PFN scaffolds [48]. Like immunotherapy drugs, chemotherapy drugs 
lead to systemic toxicity at high doses. By incorporating chemotherapy locally via the 
polymeric scaffold, researchers created a local drug delivery system to influence the TME 
while diminishing systemic toxicity. In a therapeutic efficacy study conducted over 4 
weeks, the average tumor volume of mice that received the PFN scaffold was 600 mm3 
compared to an average tumor volume of 1000 mm3 in mice that received an intraperitoneal 
injection of both chemotherapeutic drugs at equal concentrations every 3 days. This 
combinational therapy delivered by the PLGA scaffold effectively slowed tumor growth in 
a murine MDA-MB-231 orthotopic breast cancer model. 
To avoid the limitations of surgically-implanted materials (e.g. inaccessible tumor 
sites, infection), injectable scaffolds are being developed and studied to create local 
immunogenic treatments on par with implantable scaffolds. Injectable scaffolds offer many 
advantages over implantable scaffolds, particularly the ability to access hard-to-reach 
tumors that implantable scaffolds cannot reach. Some tumors are inoperable, so implanting 
a scaffold to aid in an immunotherapy cancer treatment would be hindered. However, 
injectable scaffolds could be placed close to inoperable tumor sites to enhance cancer 
treatment. Injectable scaffolds have been developed using materials including alginate [49], 
gelatin [50], and mesoporous silica rods (MSRs) [26,51], among other materials. Injectable 
scaffold materials are injected as a solution  before rapidly assembling into a 3D matrix in 
vivo that can recruit and activate immune cells or act as immunomodulatory drug 
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reservoirs. For example, injectable MSRs with a high aspect ratio can spontaneously form 
a macroporous 3D scaffold to allow for immune cell recruitment and modulation. In a study 
done by Kim and colleagues, injectable high-aspect-ratio MSRs were developed to 
assemble in vivo and recruit host immune cells by releasing GM-CSF into the surrounding 
tissue [26]. After recruitment, the immune cells, primarily DCs, could be matured using 
CpG-ODN and protein antigens. Kim and colleagues assessed the ability of the MSR 
system to induce antigen-specific adaptive immune responses. The MSR loaded with OVA, 
GM-CSF, and CpG-ODN produced strong titers for sera anti-OVA IgG2a and IgG1 which 
corresponds to strong TH1 and TH2 responses, respectively. The injectable MSR system the 
researchers developed performed better than the control bolus model containing only the 
vaccine or OVA and showed improved humoral and adaptive immune responses.  To 
further solidify the effectiveness of the purposed MSR vaccine system, Kim and colleagues 
conducted a study to investigate the ability of the delivery system to produce an antitumor 
immune response (Figure 5). Mice were vaccinated with MSR vaccines then later 
inoculated with EG7.OVA lymphoma cells. Mice vaccinated using MSR scaffolds loaded 
with OVA, GM-CSF, and CpG-ODN had tumors with significantly smaller volumes 
compared to bolus injection of the vaccine (P < 0.05), MSR scaffolds loaded with OVA 






Figure 5: Prophylactic cancer vaccine study using injectable, spontaneously forming MSR scaffolds. 
C57BL/6J mice received MSR vaccine and were challenged 10 days post-vaccination with EG7.OVA 
lymphoma cells in the back of the neck. EG7.OVA tumor volume (A) and survival rate (B) were monitored 
after tumor inoculation. In graph A, tumor volumes between treatment groups were compared on days 21, 
23, and 25. Error bars represent mean ± s.e.m. (n = 10). Data analyzed using Student’s t-test (*P < 0.05, **P 
< 0.01, ***P < 0.001). Figure adapted from Ref [26]. 
 
Scaffolds: Design Parameters 
Like hydrogels, modifying different design parameters of scaffolds can change the 
physical properties of the matrix, impact diffusivity of immunomodulatory factors to 
surrounding tissue, and bioreactivity. The physical properties of the scaffold are principally 
impacted by the choice of polymer and the fabrication process. Polymers have a specific 
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set of physical properties that are important in determining the structural stability of the 
scaffold when placed within the human body. The scaffold must be able to retain its form 
and avoid a premature collapse of the 3D matrix. In addition to considering the mechanical 
properties of the scaffold, designers also must consider the diffusive properties of the 
matrix. Like hydrogels, diffusion is an important factor for scaffolds in aiding immune cell 
recruitment and survival as well as controlled drug release. The diffusion coefficient, as 
well as the drug loading capability, of the scaffold is dependent on the porosity of the 
matrix. The pore size of scaffolds depends highly on the fabrication method used. For 
instance, one method to create a 3D matrix in the scaffold is by sparging air or carbon 
dioxide as the scaffold sets. This creates bubbles/pores in the scaffold to allow for diffusion 
and drug loading [52]. Other variations of this fabrication exist including gas generation 
from the crosslinking process. One of the simplest and oldest methods of fabrication is 
particulate leaching, or salt leaching [52]. In this method, salt or other porogens are poured 
into a mold followed by the polymer solution. Once the solvent evaporates, the salt is 
leached away with water leaving pores in the scaffold. A more controllable fabrication 
method is the use of 3D printing to create a crosslinking lattice. In the study done by Yang 
et. al., the PFN scaffold was fabricated using an E-jet 3D printer [48].  The porosity of the 
scaffolds impacts the drug release profile of the delivery device. Researchers created 
various scaffolds with different degrees of porosity by using different aperture sizes. Their 
studied showed that as aperture size increased the porosity of the scaffold increased.  
Scaffolds can be engineered by many approaches to improve immune cell 
recruitment and spatiotemporal drug release. One such route is to modify scaffold porosity. 
Injectable high-aspect-ratio MSRs nonspecifically assemble to form 3D structures 
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containing interparticle spaces, or pores. For example, researchers used MSRs with a 
hexagonal mesoporous structure and upon injection with a pore-directing agent, Pluronic® 
P-123, scaffolds with a 3D microenvironment were produced [26]. These researchers also 
tested the effect of mesopores and macropores in immune cell recruitment by looking at 
cell recruitment in 2 materials: a pore-filled silica microrod with similar qualities to MSRs 
but lacking the mesoporosity of pristine MSRs and a pressed MSR that preserved the 
mesopores but lacked macropores. Equal masses of the pore-filled MSRs, pressed MSRs, 
and untampered MSRs were injected into mice and the number of host cells recruited into 
the scaffold was analyzed on day 3. The pristine MSRs recruited approximately 2.4 * 106 
cells which was significantly higher than the pore-filled and pressed MSRs (P < 0.05). 
When comparing pore-filled MSRs to pressed MSRs, pore-filled MSRs recruited 
approximately 0.4 * 106 more cells than pressed MSRs.  This data indicates that 
interparticle macropores were vital in cell recruitment into the scaffold.  
Another way to impact the efficacy of scaffolds is through surface modification. 
Some synthetic polymers used as the basis of the scaffold have poor bioreactivity which 
can hinder cell recruitment and activation; however, this can be changed through surface 
modification. Aileen Li et. al. conducted a study analyzing the effect of surface 
modification of MSR scaffolds on immune cell recruitment and programming [27]. They 
modified the scaffold with PEG, PEG-RGD (integrin-binding ligand Arg-Gly-Asp), and 
PEG-RDG (Arg-Asp-Gly) groups. Mice received subcutaneous injections of either 
unmodified MSRs or one of the surface-modified MSRs. On day 5, the scaffolds were 
explanted and analyzed.  The total cell content of PEG modified MSRs were significantly 
higher than the cell content of unmodified MSRs (P < 0.05). The total number of cells 
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infiltrating PEG-modified MSRs was 10 times greater than unmodified MSRs and 4 times 
greater than PEG-RGD MSRs or PEG-RDG MSRs. Next, the type of immune cells that 
infiltrated that scaffold was analyzed. PEG MSRs contained a significantly lower mean 
percentage of DCs (< 1%) compared to unmodified MSRs (~4%), but the total number of 
DCs was not significantly different between the MSR scaffolds. A majority of the 
infiltrating immune cells were myeloid cells/neutrophils. PEG modified MSR scaffolds 
had a mean percentage of approximately 75%, significantly higher than the mean 
percentage of myeloid cells/neutrophils that infiltrated the unmodified MSRs (~63%), 
PEG-RGD-modified MSRs ( ~53%), and PEG-RDG-modified MSRs (~ 53%) (P < 0.05). 
MSRs modified using PEG displayed increased inflammatory responses which in turn 
increased immune cell recruitment. On the other hand, scaffolds modified with PEG-RGD 
and PEG-RDG showed decrease immune responses likely due to a hindrance in 
interactions between PEG and components of the ECM.  
 
Microparticles 
Microparticles are substantially smaller than hydrogels and scaffolds and are 
normally used to encapsulate various immunomodulatory agents including immunotherapy 
drugs and cancer vaccines. Microparticles typically range from ~1 μm  to 50 μm in 
diameter.  The large size of microparticles impacts particle diffusion and interaction with 
host cells. For instance, microparticles are taken up by immune cells, specifically APCs, 
via phagocytosis while smaller delivery systems such as nanoparticles can be taken up via 
endocytosis and micropinocytosis [53]. These particles can be loaded with cancer antigens 
and/or immunomodulatory drugs and tagged with antibodies to target immune cells. When 
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used as a cancer vaccine delivery system, microparticles protect the antigen from 
degradation normally associated with a bolus injection and are a good platform for 
synergistic combination therapies to enhance an antitumor response. Microparticles can 
serve both as local and systemic immunomodulatory biomaterials, but systemic 
applications are limited due to the large relative size of microparticles, i.e. they are too 
large to circulate. As a local immunomodulatory biomaterial, microparticles reside in the 
target/injection site to deliver therapeutics in a controlled, often sustained manner using a 
variety of drug release mechanisms (Figure 6). In this context, microparticles can be used 
alone or in conjunction with hydrogels and scaffolds. For instance, Davoodi et. al. 
formulated a treatment system that utilized a core-shell polymeric microparticle 
encapsulating cisplatin and paclitaxel embedded in an injectable hydrogel to create a novel 
localized delivery system to treat triple negative breast cancer [54]. Microparticles provide 




Figure 6: Various release mechanisms of microparticle systems. Active pharmaceutical ingredient (API). 
Figure adapted from Ref [79]. 
Microparticles: Types of Microparticles and Their Applications 
 Microparticles can be fabricated using a variety of methods, including organism-
derived, natural, and synthetic microparticles [12].  Organism-derived microparticles are 
released by cells, collected, and purified into the final material. Exosomes – extracellular 
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vesicles with cellular origin – are an example of organism-derived microparticles. Tumors 
release exosomes, containing tumor-specific antigens, when exposed to an external 
stimulus that can be used as a vaccine. For example, Zhao et. al. created tumor 
microparticles (T-MPs) by exposing B16F10 tumor cells to UV radiation [28]. After release, 
the exosomes were loaded with nano-sized Fe3O4 and CpG-loaded liposomes were attached 
to the surface of exosomes. To assess the capabilities of the Fe3O4/T-MPs-CpG/Lipo 
vaccine to produce an antitumor response, the researchers conducted a prophylactic study 
using the B16F10 melanoma tumor model (Figure 7). Mice were vaccinated on days 1, 2, 
and 7 then received an inoculation of B16F10 cells on day 8. 85.7% of the mice vaccinated 
with the Fe3O4/T-MPs-CpG/Lipo vaccine formulation remained tumor-free by the end of 













Figure 7: Murine B16F10 melanoma prophylactic study using Fe3O4/T-MPs-CpG/Lipo vaccine. C57BL/6 
mice were vaccinated on days 1, 2, and 7 followed by melanoma cell inoculation on day 8 (A). Average 
tumor growth curves (B) and the survival rate (C) were calculated during the experimental time. Error bars 
represent mean ± SD (n = 7). Data in graph B was analyzed using two-way ANOVA with the Bonferroni’s 
multiple comparison post-test and data in graph C was analyzed using the log-rank test (*P < 0.05, **P < 
0.01, ***P < 0.001). Figure adapted from Ref [28]. 
 
On day 20, tumor tissue was extracted and analyzed to assess the immunogenicity of the 
tumor. To determine the switch from a “cold” tumor to a “hot” tumor, researchers looked 
at a phenotypic switch in macrophages from pro-cancer M2 macrophages to anti-cancer 
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M1 macrophages. Vaccination with the Fe3O4/T-MPs-CpG/Lipo formulation enhanced M1 
macrophage surface marker expression compared to an empty control and the T-MPs-
CpG/Lipo vaccine. The researchers also analyzed cell suspensions from the lymph nodes 
and spleen to further demonstrate the ability of the Fe3O4/T-MPs-CpG/Lipo vaccine to 
switch macrophages to an M1 phenotype. Based on a one-way ANOVA with Bonferroni’s 
post-test, the percent of M1 macrophages was significantly higher in mice vaccinated with 
the Fe3O4/T-MPs-CpG/Lipo vaccine compared to an empty control (P < 0.001) and the T-
MPs-CpG/Lipo vaccine (P < 0.01).  By creating this newly modified tumor 
exosome/microparticle, the researchers were able to elicit a strong immune response that 
increased the immunogenicity of the TME and inhibited tumor growth.  
Natural polymer-based microparticles, such as alginate and chitosan, are 
biocompatible and readily tunable to allow for variable drug release mechanisms. In an 
early study by Lin-Shu Liu et. al., porous microspheres formed from alginate and chitosan 
were loaded with IL-2 to study the drug release profile and bioactivity of the released 
cytokine overtime [29]. The researchers conducted a protein release study with 3 
formulations of alginate microspheres using CaCl2, chitosan, and polylysine. These 
alginate microspheres were loaded with different amounts of proteins including albumin, 
bovine-fluorescein isothiocyanate (FITC-BSA), and IL-2. With a FITC-BSA protein 
loading of 10 wt%, alginate/chitosan microspheres released 45% of the payload within 6 
hrs compared to nearly 100% release by alginate/CaCl2 microspheres and 75% release by 
alginate/polylysine. Alginate/chitosan microspheres steadily released FITC-BSA over 4 
days compared to the rapid release of the protein from the other microspheres within 2 
days. Based on this preliminary data, alginate/chitosan microspheres showed promising 
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drug release profiles, so the researchers assessed release of IL-2 from these materials. Over 
a period of 5 days, alginate/chitosan microspheres steadily released 100% of the loaded IL-
2. After investigating the protein release profile of the alginate microspheres, the 
researchers assessed the ability of the alginate/chitosan microspheres to activate cytotoxic 
T lymphocytes. In this experiment, either microspheres loaded with IL-2 or free IL-2 were 
added to a cell culture of human lung squamous carcinoma SQ-5 cells and peripheral blood 
mononuclear monocytes. Activated lymphocytes were isolated from the culture at 1 week 
post treatment and 1 month post treatment to assess T cell activation over both short-term 
and long-term culture periods. After 1 week, both the microsphere delivery system and free 
administration of IL-2 yielded 4.5 * 107 activated T cells. After the 1-month culture period, 
the microsphere system yielded 80 * 107 activated T cells compared to 47 * 107 activated 
T cells by free IL-2. Alginate/chitosan microspheres steadily released IL-2 over time and 
effectively generated more activated T cells compared to free IL-2 during longer culture 
periods.  
Synthetic polymer-based microparticles are highly customizable and readily 
available for use. In a study by Rahimian et. al., poly (lactic-co-hydroxymethyl-glycolic 
acid) (pLHMGA) microparticles were loaded with either antiCD40 or antiCTLA-4 
immunomodulatory antibodies [30]. During an in vitro antibody release study, the 
microparticle initially released about 20% of the antibody payloads followed by a sustained 
release of antiCD40 or antiCTLA-4 reaching 80% drug release by day 30. The researchers 
also investigated the therapeutic efficacy of the microparticles, compared to incomplete 
Freund’s adjuvant (IFA), by treating mice inoculated with MC-38 cells, a colon carcinoma 
tumor model, when the tumor became palpable (Figure 8). 50% of the mice survived that 
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received antiCD40 antibody treatment from either IFA or from the microparticles 
compared to 10 % survival in untreated mice. A similar trend occurs in mice treated with 
antiCTLA-4 antibody treatment. 40% of the mice treated using microparticles survived and 
30 % of the mice treated with using IFA survived. Compared to untreated mice, 
significantly more mice survived after treatment with antiCD40 (P < 0.001) and antiCTLA-
4 (P < 0.01). These microparticles increased the survival rate of mice inoculated with MC-
38 tumors that was comparable to common IFA formulations. In sum, polymer chemistry 
and source play integral roles in determining the application of microparticles in cancer 
immunotherapy 
Figure 8: Therapeutic efficacy of antiCD40 and antiCTLA-4 microparticle formulation against MC-38 tumor 
cells. Kaplan-Meier plots presenting the survival proportions of tumor bearing mice treated with different 
microparticle formulations containing antiCD40 (A) and antiCTLA-4 (B). Data from two experiments (n = 







Microparticles: Design Considerations 
 The application of the microparticle greatly influences which design parameters to 
consider during fabrication. After injection, microparticles will either interact with immune 
cells, specifically phagocytes and APCs, or act as an immunomodulatory agent reservoir, 
providing controlled and sustained drug release. Microparticles that act as cancer vaccines 
or tumor antigen reservoirs should be taken in by APCs through phagocytosis. Once inside 
the APC, the microparticle is broken down in an endosome and loads freed antigen to Major 
histocompatibility complex (MHC) I and II to start the maturation process for an antitumor 
response. In a study conducted by Foged et. al., the role of particle size and surface charge 
in microparticle uptake by human DCs was investigated [31]. The researchers used 
polystyrene spheres with diameters of 0.1, 0.5, 1.0, and 4.5 μm to model microparticles. 
To assess the interaction between microparticles and dendritic cells (DCs), microparticles 
of various diameters were incubated for 24 hours with DCs and analyzed by flow cytometry 
to quantify the amount of double positive cells (indicative of microparticles bound to the 
surface of the DCs). From the flow cytometry analysis, less than 5% of DCs bonded with 
microparticles with a diameter of 4.5 μm, 10% of the DCs interacted with 1.0 μm 
microparticles, 30% of the DCs bonded with 0.5 μm microparticles, and 60% associated 
with 0.1 μm microparticles.  As particle size decreased, the number of polystyrene spheres 
bound to DCs, thus potentially endocytosed, increased. In the case of surface charge, 
different polyaminoacids/proteins were conjugated to the surface of polystyrene spheres 
with a diameter of 1 and 0.1 μm. The negatively charged particles interacted less with DCs 
compared to the particles with a positive surface charge. Based on their results, the 
researchers saw that surface charge played a bigger role in DC interaction for large particles 
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suggesting that modifying larger particles to have a positive charge could enhance DC 
uptake. On the other hand, microparticles that provide sustained release of 
immunomodulatory agents should avoid being internalized by phagocytes. For this reason, 
many physicochemical and mechanical properties can be considered to discourage 
microparticle clearance by phagocytes. A review paper to note by Moon et. al. provides an 
in-depth review of the impact of particle shape and mechanical properties on phagocyte 
interactions [32]. Microparticles are a valuable local immunomodulatory biomaterial with 















Systemic Immunomodulatory Biomaterials 
 Systemic administration of immunomodulatory drugs is a promising approach for 
the treatment of metastatic cancers that has spread to distant sites throughout the body as 
well as the treatment of primary tumors. Accordingly, the U.S. Food and Drug 
Administration has approved many immunotherapy drugs to treat metastatic cancer, e.g. 
interferons, interleukins, toll-like receptor agonists, and immune checkpoint inhibitors 
[3,5,55-56]. Even though these immunotherapies have gained FDA approval, systemic 
administration of the drugs have multiple drawbacks [55-56]. The dose of 
immunomodulatory drugs given systemically is limited by concerns about toxicity [57]. 
Additionally, large portions of the systemically administered drugs fail to reach the target 
site, instead biodistributing to other organs, limiting on-target efficacy and increasing off-
target toxicity [58-59]. Immunomodulatory drugs are rapidly excreted, degraded as they 
circulate, and accumulate at off-target sites [59]. To address the poor natural 
pharmacokinetics and biodistribution of many immunotherapeutic drugs, numerous 
immunomodulatory biomaterials have been developed for systemic delivery. Here, we 
focus our attention on two major classes of systemic delivery materials: nanoparticles and 
drug conjugates.  
Nanoparticle technology has been widely studied for the delivery of 
immunomodulatory drugs. Nanoparticles contain many customizable features that can be 
modified to: target specific immune cells or cancer cells, degrade at a pre-programmed or 
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adjustable/responsive rate, protect the immunomodulatory drug in circulation, and improve 
biodistribution to lymph nodes and/or tumors. Nanoparticles are an especially promising 
delivery system because 1) they can leverage the enhanced permeability and retention 
(EPR) effect to target tumors [60-61] and 2) recent reports show efficient accumulation of 
nanoparticles in tumor-associated leukocytes [62-63].  
Drug conjugation modifies the immunomodulatory drug itself to improve 
pharmacokinetics and biodistribution. Immunomodulatory drugs can be conjugated to 
monoclonal antibodies to target the drug to key receptors that are predominantly expressed 
on leukocytes or cancerous cells. This targeting strategy reduces off-target accumulation 
and can thus reduce systemic toxicity that results from off-target effects [59]. 
Immunomodulatory drugs can also be conjugated to synthetic polymers that serve to 
protect the drug from the harsh environment of the circulatory system as well as enhance 
the pharmacokinetics of the drug (i.e. increase the circulation half-life) [59]. By protecting 
immunomodulatory drugs using nanoparticles or conjugation methods, researchers can 
improve the efficacy of the drug, reduce dose-limiting toxicities, and create a delivery 
platform that is tunable to a variety of applications. 
 
Nanoparticles 
 Due to the systemic administration of nanoparticles, they are able to interact with a 
wide range of targets and elicit multifaceted immune responses [9,12,64]. For instance, 
nanoparticles can be leveraged to guide biodistribution to regional lymph nodes [65] and 
target immunotherapeutics to a primary tumor [36,61]. A central goal in cancer 
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immunotherapy is to activate T-cells to seek and eliminate both local and metastatic 
cancerous cells. To achieve this goal, nanoparticles are used to deliver cancer vaccines, 
antigens, and adjuvants to APCs, deliver agonists to T-cells directly, imitate APCs to 
initiate T-cell proliferation, and deliver immune checkpoint inhibitors [33]. In addition to T-
cell activation, nanoparticles protect immunotherapy drugs from degradation in the blood 
and enhance treatment by prolonging circulation time by focusing the drug biodistribution 
to specific targets [59]. Importantly, a wide range of nanoparticles have been developed that 
are either approved by the FDA or currently progressing through clinical trials [36]. By 
continued improvement in our understanding of tumor immunobiology, advancements in 
materials chemistry and nanotechnology, and effective interdisciplinary collaboration 
between immunologists and biomedical engineers, the development of more FDA-
approved products that can have a major impact on cancer immunotherapy are underway.   
Immunotherapeutic drugs face a wide range of obstacles, such as cellular uptake 
and trafficking barriers, depending upon the type of drug (e.g. small molecule, antibody, 
nucleic acid) and intracellular destination (Figure 9). Upon encountering an appropriate 
APC, nanoparticles should trigger internalization into the targeted cell. Upon 
internalization, fate of the nanoparticles and accompanying immunotherapeutic drugs can 
be tuned to suit the intended application. For instance, immunotherapies for endosomal 
targets (e.g. TLR7/8 agonists and antigens for MHC-II) necessitate cell uptake via 
endocytosis but do not require endosomal escape, whereas immunotherapies for cytosolic 
targets (e.g. 5’pppRNA and mRNA vaccines) require both cell uptake and efficient 
endosomal escape. In a study done by Oberli et al.[34], lipid nanoparticles were used to 
transfect APCs with an mRNA vaccine coding for two melanoma self-antigens: tyrosinase-
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related protein 2 (Trp2) and glycoprotein 100 (gp100) with a point mutation. Vaccination 
with the lipid nanoparticles greatly increased the number of transfected APCs and 
increased CD8 T cell proliferation thus increasing the survival rate of mice with B16F10 
tumors. By using a lipid nanoparticle, the researchers were able to effectively address the 
delivery challenges of using mRNA vaccines. The lipid nanoparticles employed by this 
group consisted of 5 components: an ionizable lipid, a phospholipid, cholesterol, PEG 
containing lipids, and an additive for mRNA vaccine delivery. Each of these components 
aid in the processes of biodistribution, cellular uptake, and endosomal escape. The 
ionizable lipid becomes positively charged at lower pH to aid in conjugation to mRNA and 
the positive charge aids in cellular uptake and endosomal escape. By incorporating 
phospholipids and cholesterol into the lipid nanoparticle, researchers help stabilize the 
particle and help with endosomal escape. By using PEG-lipid conjugates in the 





Figure 9: Schematic of cell targeted delivery of immunotherapeutic agents using nanoparticles. Composed 
of three steps: i) the nanoparticle binds to specific receptors of the cell, ii) endocytic uptake of the nanoparticle 
through receptor-mediated endocytosis, and iii) immunotherapeutic agent release via endosomal escape. 
Figure adapted from Ref [39]. 
 
In another study done by Xu et. al., researchers used a nanoparticle composed of a 
calcium phosphate (CaP) core and an asymmetric lipid bilayer (lipid-calcium-phosphate 
(LCP) nanoparticle) to deliver a peptide vaccine of Trp2 to mouse models of melanoma 
(B16F10) [35]. The goal of the study was to elicit MHC I-restricted cytotoxic T-lymphocyte 
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responses to eradicate B16F10 tumors. In order for the peptide to be effective in creating 
an immune response, the nanoparticle has to deliver the vaccine to the cytosol of the APC. 
To achieve this goal, Xu and colleagues modified the surface of the nanoparticle with 
mannose to bind to mannose receptors of APCs and aid in cellular uptake. Additionally, 
LCP nanoparticles have two mechanisms of endosomal escape depending on the number 
of nanoparticles taken in by the APC [66].  If large quantities of LCP nanoparticles are 
endocytosed, endosomal escape occurs due to an increase in osmotic pressure in the acidic 
environment of the endosome that results in the dissolution of the CaP core. If smaller 
quantities of LCP nanoparticles are endocytosed, endosomal escape results from the 
formation of ion pairs between the cationic lipids in the asymmetric bilayer, 
dioleoylphosphatydic acid (DOTAP), and negatively charged groups in the endosomal 
membrane. On the other hand, some nanoparticles do not have to be endocytosed by APCs 
to elicit an immune response. For example, researchers can conjugate MHC and antigen 
complexes to the surface of nanoparticles to create artificial APCs that can activate T cells 
[67]. By following similar design processes, nanoparticles can be synthesized that efficiently 
deliver immunotherapeutics to a variety of intracellular targets; endosomal, cytosolic, and 
otherwise. 
 
Nanoparticles: Design Considerations 
Nanoparticles can be fabricated using a variety of methods; however, there are key 
design parameters that must be considered in order to create an effective delivery system. 
The size of nanoparticles plays a key role in nanoparticle accumulation at tumor sites and 
clearance by phagocytes. Though the EPR effect is variable and mechanisms to better 
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understand nanoparticle accumulation in tumors are being investigated, tumors that contain 
leaky vasculature and impaired lymphatic drainage allow circulating nanoparticles to 
preferentially infiltrate the tumor and avoid clearance from the tumor site. One study of 
note was conducted by Perrault et. al. to systematically study how particle size (10-100 
nm) influenced the pharmacokinetics of nanoparticles [37]. One of the experiments 
conducted by the researchers investigated the tumor accumulation of nanoparticles with 
varying sizes (20 nm, 40 nm, 60 nm, 80 nm, and 100 nm). Each size bracket showed 
different levels of accumulation in the tumor site; however, the researchers saw no clear 
trend between particle size and tumor accumulation. In the researchers’ model, the lack of 
correlation between particle size and tumor site accumulation should be reflected by a 
dependence on blood/circulation half-life over time. After doing a regression analysis, the 
researchers found that this phenomenon was only significant for particle sizes ranging from 
40-100 nm (P < 0.02). This suggests that the size of smaller nanoparticles may affect tumor 
accumulation. To investigate this further, the researchers conducted another regression 
analysis that considered volumetric size of the nanoparticles (nm3) and half-life. This 
analysis revealed a significant relationship in particle sizes ranging from 20 nm to 100 nm 
diameter in relation to half-life (P < 0.015). This regression analysis showed that the 
accumulation of nanoparticles around 20 nm depends on its size and half-life. On the other 
hand, particles ranging from 40-100 nm depends almost entirely on circulation half-life 
indicating a possible route to modify tumor accumulation by modifying pharmacokinetic 
parameters. Another important design factor brought to light by the study is the impact of 
size on the permeation of nanoparticles. Generally, as particle size increased, the area of 
permeation within tumors became smaller. In summation, these results show that 
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nanoparticle size profoundly impacts the amount of nanoparticle accumulation and 
homogeneity in the tumor site. Thus, researchers must determine the acceptable size range 
for nanoparticles to optimize accumulation and permeation for their particular application 
– though for most cases nanoparticles in smaller size ranges (~20-50 nm) appear most 
suitable. 
Other key design considerations include the material of the particle, surface charge, 
and degradation mechanism [38,39].  For instance, nanoparticles composed of PEG are 
generally non-toxic and non-immunogenic, whereas poly(beta-amino esters) becomes 
immunogenic as they are degraded over time [76]. Surface charge is an important parameter 
with regards to cellular uptake and circulation time. Nanoparticles with a positively-
charged surface have a higher rate of cellular uptake while neutral and slightly negatively-
charged surfaces reduce cellular uptake. Due to the increased cellular uptake of positively-
charged nanoparticles, in addition to rapid protein adsorption and aggregation, these 
particles generally have very short circulation times. For this reason, charged materials are 
often coated with materials like PEG to shield surface charge, increase biocompatibility, 
and prevent particle clearance by the MPS system. The degradation mechanism and drug 
release trigger can be modified to suit a wide range of applications. Some of these triggers 
include tumor hypoxia, low pH of endosomes and TME, tumor-specific enzymes, and 
oxidative stress. These triggers cause biodegradation of the nanoparticle material while 
also enabling a mechanism for drug release from the particles. For further analysis, please 
see the extensive review on linker chemistry design and nanoparticle drug release by Wong 




Nanoparticles: Types of nanoparticles and Their Applications 
Nanoparticles are one of the most customizable biomaterials/delivery systems used 
in research. They can be created from a range of polymers and biological agents including 
synthetic polymers like PEG, lipids/lipid-like materials, natural polymers like hyaluronic 
acid, and inorganic metals like gold [64]. Similar to composite hydrogels and scaffolds, 
hybrid nanoparticles can be produced by combining different material classes into 
composites to leverage positive characteristics of each material. Researchers have 
engineered many types of nanoparticles including silica nanoparticles, dendrimers, carbon 
nanoparticles, ceramic nanoparticles, etc. [68,69]. The three types of nanoparticles discussed 
here are lipid-based, synthetic polymer-based, and natural polymer-based.  
Lipid-based nanoparticles and liposomes are primarily composed of lipids and 
follow the design criteria of vesicles. The lipid-based nanoparticles can be composed of an 
ionizable lipid, phospholipids, cholesterol, PEG-lipids, and additives to aid in drug/vaccine 
delivery. Liposomes are primarily composed of either natural or synthetic lipids. They can 
have single or multiple lipid bilayers with an aqueous core to house both hydrophobic and 
hydrophilic immunomodulatory agents/drugs. A key advantage of lipid nanoparticles is the 
ease of conjugating ligands to the surface of the particle. The conjugation of ligands gives 
nanoparticles the ability to target key immune cells and encourage cellular uptake. In a 
study done by Zhang et. al., the surface of PEGylated liposomes were coated with IL-2 
agonists and anti-CD137 ligands to stimulate the proliferation of cytotoxic T lymphocytes 
and natural killer (NK) cells as well as act as a co-stimulatory signal for T cell activation 
[40]. The researchers first assessed the effectiveness of a combinational treatment with anti-
CD137 and IL-2-Fc, a fusion of the Fc domain to IL-2 to prolong circulation half-life, 
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against the B16F10 melanoma model. Mice with established B16F10 tumors received 
systemic injections of 20 μg of IL-2-Fc and 100 μg of anti-CD137 every 2 days for a total 
of 3 doses. The mice treated with anti-CD137/IL-2-Fc had smaller average tumor sizes 
compared to untreated mice; however, the mice experience severe systemic toxicity along 
with rapid weight loss that ultimately led to death by the third injection. Additionally, using 
a longer time interval between doses (1 week) did not mitigate systemic toxicity in the 
mice. On the other hand, lowering the doses decreased the level of toxicity but it also 
reduced the treatments effectiveness against B16F10 melanomas. Treatment with anti-
CD137/IL-2-Fc caused a dose-dependent systemic cytokine storm resulting in heightened 
cytokine levels. By conjugating these immune agonists to the surface of liposomes, the 
researchers were able to eliminate the toxic side effects, indicated by rapid weight loss and 
elevated cytokine levels, associated with systemic administration of IL-2 and CD137 
antibodies. As seen in Figure 10, mice treated with the modified liposome had significantly 
delayed tumor growth compared to an isotype control liposome (Lipo-IgG) and 
systemically administered anti-CD137/IL-2-Fc (P < 0.05) and maintained constant body 
weight which signifies the absence of systemic toxicity. Furthermore, mice that were 
treated with the immunoliposome had a significantly higher survival percent compared to 
the untreated group, the free IL-2-Fc/αCD137 treatment group, and the liposome control 
group (P < 0.001) For more information, a detailed review on liposomes and lipid 
nanoparticle drug delivery systems was written by Kraft and his colleagues [41].  
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Figure 10: Therapeutic efficacy of immunoliposome IL-2-Fc/αCD137 therapy. Groups of C57BL/6 mice 
were inoculated with B16F10 melanoma cells followed by systemic injections of treatment groups on days 
8, 10, 12, and 14 post inoculation. Data shows mean tumor sizes (A), relative body weight indicative of 
systemic toxicity (B), and overall survival of mice (C). Error bars represent mean ± s.e.m. (n = 6-7 per group). 
Data analyzed using two-tailed Student’s t-test (*P < 0.0005, ***P < 0.001). Figure adapted from Ref [40]. 
 
One of the most common materials used for fabricating nanoparticles are synthetic 
polymers due to their ease and affordability of synthesis, wide availability, and 
customizability. Synthetic nanoparticles made from materials like PLGA and PEG allow 
for a controlled release of immunomodulatory agents to prolong the effect of the drug while 
minimizing potential side effects. Synthetic nanoparticles also allow for a modifiable 
platform to control pharmacokinetic parameters, control biodistribution, and control 
targeting specificity. In a study done by Schmid et. al., nanoparticles made from FDA-
approved PLGA and PEG were designed to target T cells that commonly infiltrate the TME 
and “hitchhike” to the tumor site before releasing SD-208, a TGFβRI kinase inhibitor [42]. 
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TGFβ plays a role in immunosuppression in the TME [77], so by administering SD-208 the 
researchers hope to reverse the immunosuppressive TME. To establish the T-cell targeting 
system, the researchers conjugated anti-PD-1 antibody fragments to the surface of the 
PLGA/PEG nanoparticle to target CD8+ T-cells that were PD-1+ because these T-cells 
frequently infiltrated the tumor site [78]. To assess the therapeutic potential of the 
nanoparticle delivery system, the researchers conducted in vivo studies using the MC38 
colorectal cancer model (Figure 11). Mice were inoculated with MC38 tumor cells. After 
5 days, mice were administered the nanoparticle formulation or free drugs (20μg anti-PD-
1 and 40μg SD-208) and received subsequent doses every other day up to a total of 10 
doses. Free administration of the drugs had no reductive effects on tumor growth, but tumor 
growth was delayed when the SD-208 was delivered using the PD-1 targeting 
nanoparticles. Additionally, the survival rate of mice treated with this nanoparticle 
formulation was significantly higher compared to the other treatment groups (P < 0.001). 
However, tumor growth in mice treated with the forementioned nanoparticle formulation 
continued to progress until it reached a tumor volume of 2000 mm3, like the untreated and 
free drug groups but delayed by 7 days. Even though immune evasion prevailed in this 
tumor model, the nanoparticle formulation was able to delay growth and offers a platform 
for further modification to create a synergistic therapy that will utilize the niche of hindered 





Figure 11: Therapeutic effect of targeted delivery of SD-208 (a TGFβR1 inhibitor) using anti-PD-1 tagged 
nanoparticles. C57BL/6 mice were inoculated with MC38 cells and treatment with nanoparticle formulations 
or free drugs occurred 5 days post inoculation. Mice received subsequent doses every other day up to a 
maximum of 10 doses. Tumor volume (A) and mice survival (B) was monitored over course of study. Error 
bars represent mean ± s.e.m. (n = 6). Data analyzed using Mantel-Cox test (***P < 0.001). Figure adapted 
from Ref [78]. 
 
In a subsequent study done by the researchers to repurpose the nanoparticle targeting 
system, the researchers considered the possibility of eliciting an inflammatory response in 
the TME by delivering a Toll-like receptor (TLR) 7/8 agonist, R848, to make the MC38 
tumor more sensitive to immune checkpoint blockade therapy. The researchers conducted 
another in vivo study using R848 instead of SD-208 (Figure 12). Mice were inoculated 
with MC38 tumor cells and received doses on day 5 followed by doses every other day for 
a maximum of 10 doses. The delivery of R848 using PD-1 targeted nanoparticles 
significantly delayed tumor growth compared to untreated mice and mice that received free 
drugs (P < 0.05) and significantly more of the mice treated with the nanoparticles survived 
at the end of the study (P < 0.001). Synthetic nanoparticles allow researchers to easily 
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customize the surface and structure of the nanoparticle to optimize immunotherapeutic 
drug delivery. 
Figure 12: Therapeutic effect of targeted delivery of R848 (a TLR7/8 agonist) and sensitization of tumors to 
PD-1 blockade. C57BL/6 mice were inoculated with MC38 tumor cells followed by nanoparticle or free drug 
treatment on day 5 and every other day for a total of 10 doses. Tumor volume and animal survival were 
monitored to assess efficacy (A,B). For graph C-D, nanoparticle or free drug treatment were administered on 
days 5, 7, and 9 after tumor inoculation to inflame the tumor. Mice were then treated on days 11, 14, and 17 
with anti-PD-1 antibody through intraperitoneal injection. Tumor volume and animal survival were 
monitored to assess efficacy (C,D). Error bars represent mean ± s.e.m. (n = 6-7). Data analyzed using Mantel-
Cox test (*P < 0.05, ***P < 0.001). Figure adapted from Ref [78]. 
 
Natural polymeric nanoparticles are fabricated using polymers derived from natural 
compounds. Natural compounds like HA, alginate, and chitosan have the advantage of 
intrinsic biodegradability and biocompatibility. Drawbacks of using natural polymers 
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include the variability between batches, potential for contamination, and difficulty to scale 
synthesis. In a study done by Shi et. al., chitosan nanoparticles with mannose ligands 
conjugated to the surface were loaded with whole tumor cell lysates (Man-CTS-TCL 
nanoparticles) to act as a cancer vaccine that targets specific DCs [70]. One of the studies 
conducted by the researchers assessed the prophylactic capabilities of the nanoparticle 
vaccine formulation when challenged by an inoculation of 1*105 B16 tumor cells. 
Vaccination using Man-CTS-TCL nanoparticles delayed tumor growth resulting in a mean 
tumor volume less than 500 mm3 21 days after tumor cell inoculation. The tumor volume 
in mice vaccinated with Man-CTS-TCL was significantly smaller than the tumor volume 
in untreated mice (P < 0.05), in mice vaccinated only by using tumor cell lysates, in mice 
treated with chitosan nanoparticles lacking mannose ligands (P < 0.05), and in mice treated 
with chitosan nanoparticles with mannose ligands but lacking the tumor cell lysate payload 
(P < 0.05). To further solidify the conclusion that Man-CTS-TCL nanoparticles are an 
effective vaccination system, the researchers assessed the therapeutic effects of the 
nanoparticles by vaccinating mice 7 days after receiving subcutaneous injections of B16 
melanoma cells. Similar to the prophylactic study, Man-CTS-TCL nanoparticles 
significantly inhibited B16 tumor growth compared to the untreated group (P < 0.05). 
Nanoparticles made from natural polymers have intrinsic biodegradable and biocompatible 
properties. Nanoparticles are a highly customizable drug delivery platform that can be used 
to suit a variety of immunotherapeutic applications ranging from delivering cancer 






 Drug conjugation is a simple and effective modification strategy to improve the 
efficacy of systemically administered immunomodulatory drugs. In drug conjugation, 
immunomodulatory agents are simply conjugated to a targeting ligand, normally a 
monoclonal antibody, or synthetic polymers to modify the pharmacokinetics of the 
agents/drugs and minimize their side effects.   The two categories of drug conjugates 
reviewed here are antibody-drug conjugates and polymer-drug conjugates. In cancer 
immunotherapy, antibodies used alone can recognize specific antigens on or near the tumor 
site to elicit a cytotoxic response, but the curative effects are limited unless the monoclonal 
antibodies are modified through conjugation [72].  Antibody-drug conjugates utilize the 
targeting capabilities of monoclonal antibodies and the cytotoxic/immunotherapeutic 
effects of the conjugated drug [72,73]. The basic design of these conjugations consists of the 
antibody, a linker, and the drug. Any of these three components can be modified to create 
the best drug delivery system for the intended application [43].  Polymer-drug conjugation 
allows researchers to modify the pharmacokinetics of immunotherapy drugs, protect the 
drug from the environment, and allow for the conjugation of targeting moieties [44]. For 
instance, conjugating immunotherapeutic or cytotoxic drugs to a synthetic polymer such as 
PEG protects the drugs from enzymatic degradation and rapid clearance via the liver and 
kidneys [74,75]. As a result, polymer-drug conjugates generally increase circulation time 
compared to the parent drug. Polymer-drug conjugates depend on passive accumulation at 
tumor sites and can be further modified with targeting ligands in order to bind specific 
immune cell targets or cancer cells [44]. Many classes of polymer-drug conjugates exist 
including polymers conjugated to biological proteins, small molecule drugs conjugated to 
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a long polymeric chain, dendrimers, and others. These various conjugate arrangements can 
elicit different pharmacokinetics and incorporate drug release mechanisms to create the 
desired therapeutic effect [44]. Conjugating small-molecule drugs to polymer chains offers 
several advantages such as improved solubility, increased drug stability, prolonged 
circulation half-life, and altered biodistribution [74]. Conjugating polymers to biological 
proteins shield the antigenic epitopes through steric hindrance as well as shields the protein 
from circulating proteolytic enzymes and the MPS. The improved pharmacokinetics of 
biological proteins reduces the dosage thus improving the safety of treatment. Today, many 
drug conjugates have been approved by the FDA or are being tested in clinical trials [44,73].  
Current advances in oncology research have primarily used antibody- and polymer-
drug conjugation to deliver cytotoxic drugs; however, it is theoretically possible to replace 
the drug component with common immunotherapies in future generations [43,44]. By 
conjugating drugs to polymers and/or antibodies, researchers achieve a slower clearance 
rate, prolonged drug circulation, and can potentially alleviate toxic side effects and the risk 
of autoimmunity associated with systemic immunotherapy.  
Polymer-Drug Conjugates: Design Considerations 
 The first rational model for “polymeric prodrugs”, or polymer-drug conjugates, was 
created by Professor Helmut Ringsdorf in 1975 [45]. These conjugates had five major 
components: a solubilizer compound, the drug, the polymer backbone, spacers, and a 
transport/targeting component. Any of these components can be modified to alter the 
pharmacokinetics and biodistribution of the drugs. The polymer choice for the backbone 
dictates which drugs can be conjugated, the biocompatibility of the drug conjugate, 
biodegradation and clearance rate, and drug stability. One of the most important design 
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considerations is the type of linker between the polymer and the drug. Through the 
manipulation of linker chemistry, the release mechanism can be modified to focus drug at 
the targeted site. This is especially important in preventing off-target drug release while in 
circulation. These linkers can be pH-responsive, degradable by enzymes present at high 
levels at tumor sites, or responsive to lysosomal enzymes. For example, Lv et al. conjugated 
paclitaxel (PTX), a cancer therapeutic drug, to 3,3’-dithiodipropionic acid functionalized 
methoxy poly(ethylene glycol)-b-poly(L-lysine) (mPEG-b-P(LL-DTPA)) to form a 
polymer-PTX drug conjugate (P(L-SS-PTX)) [46].  In this case, the conjugate linker is a 
disulfide bond between the carboxyl groups of mPEG-b-P(LL-DTPA) and PTX which is 
unstable in reductive and acidic environments. This mechanism allows for drug release 
once the drug conjugate is taken into the cell’s endolysosomal pathway. This polymer-drug 
conjugate can also be released in the extracellular matrix of the tumor due to the lower pH 
and high concentrations of glutathione (GSH). During an in vitro drug release study, drug 
release from P(L-SS-PTX) was slow, releasing less than 8% of the conjugated PTX, over 
the time frame of the study (120 hours) when placed in an extracellular environment that 
mimics the TME (pH of 7.4 with a concentration of 20 μM GSH). However, when the 
concentration of GSH is increased to 10 mM, P(L-SS-PTX) rapidly releases more than 
75% of the PTX over the 120-hour time frame of the study. To simulate the environment 
of an endosome, the drug release profile was analyzed in an environment with a pH of 5. 
P(L-SS-PTX) released approximately 50% of the PTX payload over 120 hours. Overall, 
their drug design barely released any of the cytotoxic drug in neutral environmental 
conditions but released a majority of the payload in the acidic and reductive environments. 
Additionally, the researchers conducted an in vivo antitumor activity study using the B16F1 
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melanoma tumor model to assess the therapeutic capabilities of P(L-SS-PTX) compared to 
untreated mice, mice systemically administered PTX, and mice injected with P(L-PTX), a 
similar polymer-PTX conjugate that lacks disulfide bonds (Figure 13). Mice injected with 
P(L-SS-PTX) had an average tumor volume of approximately 250 mm3 which was 
significantly lower than the tumor volume of mice injected with P(L-PTX) (P < 0.01) and 
systemically administered PTX (P < 0.001). The drug conjugate effectively hindered tumor 
growth without toxic side effects, as indicated by a lack of weight loss, compared to free 
systemic administration of paclitaxel and the drug conjugate lacking the disulfide linker. 
This study did not focus on the use of an immunotherapy; however, it serves as a proof of 
concept that can be applied to other immunotherapeutic agents.  
Figure 13: In vivo anti-tumor efficacy of P(L-SS-PTX), a polymer-paclitaxel drug conjugate. C57BL/6 mice 
were inoculated with B16F1 melanoma cells and tumor volume was allowed to grow until it achieved a tumor 
volume of approximately 20-30 mm3. Mice were treated with (a) PBS, (b) free PTX, (c) P(L-PTX), or (d) 
P(L-SS-PTX). Tumor volume (A) and body weight change (B) was assessed for treatment efficacy. Error 
bars represent mean ± SD (n = 6). Data analyzed using Student’s t-test (*P < 0.05, **P < 0.001, #P < 0.001). 




 Antibody-Drug Conjugates: Design Considerations  
  Antibody-drug conjugates have similar design considerations as polymer-drug 
conjugates; however, antibodies provide a mechanism to target specific cell populations 
such as tumor cells or tumor leukocytes via receptor-ligand binding. The basic design 
components of antibody-drug conjugates are the antibody, the drug, and the linker. When 
considering which antibody to use for the conjugation, researchers should consider an 
antigen overexpressed on tumor cells (or tumor-associated leukocytes) but not expressed 
on normal, healthy cells. In a review done by Perez et al., a list of target antigens for various 
types of cancer is provided [43].  Once an antibody is chosen that will provide specific 
binding, other properties must be considered such as antibody stability after conjugation, 
in systemic transit, and at the site of targeted tumor or immune cells. Like polymer-drug 
conjugates, the linker plays an important role in the stability and drug release of antibody-
drug conjugates. These linker components can be sensitive to lysosomal enzymes, pH-
responsive, or responsive to glutathione (a reducing agent). Some antibody-drug 
conjugates utilized non-cleavable linkers. In these cases, the payload can only be released 
once the conjugate is taken into the cell and the antibody is degraded. After determining 
the best antibody and linker to suit the application, the site of conjugation onto the antibody 
is another important consideration as the conjugation site greatly impacts the activity of 
the drug conjugate. Most researchers use alkylation of reduced interchain disulfides, 
acylation of lysine residues, or alkylation of genetically engineered cysteine residues to 
combine the drug and linker to the antibody [47]. Figure 14 provides an overview of the key 
design components of antibody-drug conjugates. Antibody-drug conjugations gives 
researchers the ability to target key cells to elicit an antitumor response and warrant further 
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research to determine effective designs that can deliver immunomodulatory agents to 
tumors and associated immune cells/organs.  
Figure 14: Key design components of antibody-drug conjugates. PK, pharmacokinetics. Figure adapted from 

















The development of immunomodulatory treatments has made tremendous strides 
since the FDA approval of IFN-α to treat leukemia. Cancer immunotherapy has become a 
vital asset for oncologists to treat cancer that has proven resistant to typical cancer therapies 
including radiotherapy and chemotherapy. Immunotherapy offers a less toxic alternative 
that has long-term curative effects to inhibit cancer growth, metastasis, and recurrence. 
Though widely successful, many immunomodulatory agents in use are not effective in 
patients with tumors that lack immunogenicity and can have adverse side effects when used 
at high doses for long treatment windows. To solve these issues, researchers have 
developed a wide range of biomaterials that can be used to deliver drugs systemically and 
locally. By using these immunomodulatory biomaterials, researchers can target specific 
immune cells and cancer cells, improve the pharmacokinetics and biodistribution of 
immunotherapies, and improve the therapeutic window of approved and experimental 
immunotherapies. As a result of the targeted delivery systems, biomaterials effectively use 
low doses of immunomodulatory drugs such as IL-2, PD-1, or PD-L1 to elicit an effective 
anticancer immune response without toxic side effects. Biomaterials also offer a modifiable 
platform for spatiotemporal drug release to promote controlled, long-term, and responsive 
treatments. Each biomaterial discussed in this review has key features that suit the intended 
application of cancer immunity treatment. When considering an effective biomaterial for 
immunomodulation, researchers must investigate which design parameters best suit their 
intended use. Accordingly, we have reviewed hydrogels, scaffolds, microparticles, 
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nanoparticles, and drug conjugates. The key design criteria of each biomaterial were 
discussed, with a main focus on the effect of physical characteristics of the biomaterial on 
drug delivery and its application. Immunomodulatory biomaterials such as those discussed 
within this article have the potential to revolutionize cancer immunotherapy and improve 


















1. Kandalaft, Lana E., Nathan Singh, John B. Liao, Andrea Facciabene, Jonathan S. 
Berek, Daniel J. Powell, and George Coukos. “The Emergence of 
Immunomodulation: Combinatorial Immunochemotherapy Opportunities for the 
next Decade.” Gynecologic Oncology, Novel Therapies for Gynecologic 
Malignancies, 116, no. 2 (February 1, 2010): 222–33. 
https://doi.org/10.1016/j.ygyno.2009.11.001. 
 
2. D’Errico, Gabriele, Heather L. Machado, and Bruno Sainz. “A Current Perspective 
on Cancer Immune Therapy: Step-by-Step Approach to Constructing the Magic 
Bullet.” Clinical and Translational Medicine 6, no. 1 (2017): 3. 
https://doi.org/10.1186/s40169-016-0130-5. 
 
3. Oiseth, Stanley J., and Mohamed S. Aziz. “Cancer Immunotherapy: A Brief 
Review of the History, Possibilities, and Challenges Ahead.” Journal of Cancer 
Metastasis and Treatment 3, no. 10 (October 31, 2017): 250. 
https://doi.org/10.20517/2394-4722.2017.41. 
 
4. Tan, Shuzhen, Dongpei Li, and Xiao Zhu. “Cancer Immunotherapy: Pros, Cons and 
Beyond.” Biomedicine & Pharmacotherapy 124 (April 2020): 109821. 
https://doi.org/10.1016/j.biopha.2020.109821. 
 
5. Lee, Sylvia, and Kim Margolin. “Cytokines in Cancer Immunotherapy.” Cancers 
3, no. 4 (December 2011): 3856–93. https://doi.org/10.3390/cancers3043856. 
 
6. Kaunitz, Genevieve J., Manisha Loss, Hira Rizvi, Sowmya Ravi, Jonathan D. Cuda, 
Karen B. Bleich, Jessica Esandrio, et al. “Cutaneous Eruptions in Patients 
Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Non-
Lichenoid Histologic Pattern.” The American Journal of Surgical Pathology 41, no. 
10 (October 2017): 1381–89. https://doi.org/10.1097/PAS.0000000000000900. 
 
7. Koshy, Sandeep T, and David J Mooney. “Biomaterials for Enhancing Anti-Cancer 
Immunity.” Current Opinion in Biotechnology 40 (August 2016): 1–8. 
https://doi.org/10.1016/j.copbio.2016.02.001. 
 
8. Riley, Rachel S., Carl H. June, Robert Langer, and Michael J. Mitchell. “Delivery 
Technologies for Cancer Immunotherapy.” Nature Reviews Drug Discovery 18, 
no. 3 (March 2019): 175–96. https://doi.org/10.1038/s41573-018-0006-z. 
 
9. Cheung, Alexander S., and David J. Mooney. “Engineered Materials for Cancer 





10. Kearney, Cathal J., and David J. Mooney. “Macroscale Delivery Systems for 
Molecular and Cellular Payloads.” Nature Materials 12, no. 11 (November 2013): 
1004–17. https://doi.org/10.1038/nmat3758. 
 
11. Dellacherie, Maxence O., Bo Ri Seo, and David J. Mooney. “Macroscale 
Biomaterials Strategies for Local Immunomodulation.” Nature Reviews Materials 
4, no. 6 (June 2019): 379–97. https://doi.org/10.1038/s41578-019-0106-3. 
 
12. Huang, Pingsheng, Xiaoli Wang, Xiaoyu Liang, Jing Yang, Chuangnian Zhang, 
Deling Kong, and Weiwei Wang. “Nano-, Micro-, and Macroscale Drug Delivery 
Systems for Cancer Immunotherapy.” Acta Biomaterialia 85 (February 2019): 1–
26. https://doi.org/10.1016/j.actbio.2018.12.028. 
 
13. Chai, Qinyuan, Yang Jiao, and Xinjun Yu. “Hydrogels for Biomedical 
Applications: Their Characteristics and the Mechanisms behind Them.” Gels 3, no. 
1 (January 24, 2017): 6. https://doi.org/10.3390/gels3010006. 
 
14. Kim, Jihoon, Margaret P. Manspeaker, and Susan N. Thomas. “Augmenting the 
Synergies of Chemotherapy and Immunotherapy through Drug Delivery.” Acta 
Biomaterialia 88 (April 2019): 1–14. https://doi.org/10.1016/j.actbio.2019.02.012. 
 
15. Chyzy, Adam, Monika Tomczykowa, and Marta E. Plonska-Brzezinska. 
“Hydrogels as Potential Nano-, Micro- and Macro-Scale Systems for Controlled 
Drug Delivery.” Materials 13, no. 1 (January 2, 2020): 188. 
https://doi.org/10.3390/ma13010188. 
 
16. Singh, Ankur, and Nicholas A. Peppas. “Hydrogels and Scaffolds for 
Immunomodulation.” Advanced Materials 26, no. 38 (October 2014): 6530–41. 
https://doi.org/10.1002/adma.201402105. 
 
17. Peppas, N. A., Y. Huang, M. Torres-Lugo, J. H. Ward, and J. Zhang. 
“Physicochemical Foundations and Structural Design of Hydrogels in Medicine 
and Biology.” Annual Review of Biomedical Engineering 2, no. 1 (August 2000): 
9–29. https://doi.org/10.1146/annurev.bioeng.2.1.9. 
 
18. Kirschner, Chelsea M., and Kristi S. Anseth. “Hydrogels in Healthcare: From Static 
to Dynamic Material Microenvironments.” Acta Materialia 61, no. 3 (February 
2013): 931–44. https://doi.org/10.1016/j.actamat.2012.10.037. 
 
19. Lau, Hang Kuen, and Kristi L. Kiick. “Opportunities for Multicomponent Hybrid 
Hydrogels in Biomedical Applications.” Biomacromolecules 16, no. 1 (January 12, 
2015): 28–42. https://doi.org/10.1021/bm501361c. 
 
20. Lee, Kuen Yong, and David J. Mooney. “Hydrogels for Tissue Engineering.” 






21. Kharkar, Prathamesh M., Kristi L. Kiick, and April M. Kloxin. “Designing 
Degradable Hydrogels for Orthogonal Control of Cell Microenvironments.” Chem. 
Soc. Rev. 42, no. 17 (April 22, 2013): 7335–72. 
https://doi.org/10.1039/C3CS60040H. 
 
22. Duong, Huu Thuy Trang, Thavasyappan Thambi, Yue Yin, Seong Han Kim, Thanh 
Loc Nguyen, V.H. Giang Phan, Jaeyun Kim, Ji Hoon Jeong, and Doo Sung Lee. 
“Degradation-Regulated Architecture of Injectable Smart Hydrogels Enhances 
Humoral Immune Response and Potentiates Antitumor Activity in Human Lung 
Carcinoma.” Biomaterials 230 (February 2020): 119599. 
https://doi.org/10.1016/j.biomaterials.2019.119599. 
 
23. Lv, Qiang, Chaoliang He, Fenli Quan, Shuangjiang Yu, and Xuesi Chen. “DOX/IL-
2/IFN-γ Co-Loaded Thermo-Sensitive Polypeptide Hydrogel for Efficient 
Melanoma Treatment.” Bioactive Materials 3, no. 1 (March 2018): 118–28. 
https://doi.org/10.1016/j.bioactmat.2017.08.003. 
 
24. Ali, Omar A., Nathaniel Huebsch, Lan Cao, Glenn Dranoff, and David J. Mooney. 
“Infection-Mimicking Materials to Program Dendritic Cells in Situ.” Nature 
Materials 8, no. 2 (February 2009): 151–58. https://doi.org/10.1038/nmat2357. 
 
25. Smith, Tyrel T., Howell F. Moffett, Sirkka B. Stephan, Cary F. Opel, Amy G. 
Dumigan, Xiuyun Jiang, Venu G. Pillarisetty, Smitha P. S. Pillai, K. Dane Wittrup, 
and Matthias T. Stephan. “Biopolymers Codelivering Engineered T Cells and 
STING Agonists Can Eliminate Heterogeneous Tumors.” Journal of Clinical 
Investigation 127, no. 6 (April 24, 2017): 2176–91. 
https://doi.org/10.1172/JCI87624. 
 
26. Kim, Jaeyun, Weiwei Aileen Li, Youngjin Choi, Sarah A Lewin, Catia S Verbeke, 
Glenn Dranoff, and David J Mooney. “Injectable, Spontaneously Assembling, 
Inorganic Scaffolds Modulate Immune Cells in Vivo and Increase Vaccine 
Efficacy.” Nature Biotechnology 33, no. 1 (January 2015): 64–72. 
https://doi.org/10.1038/nbt.3071. 
 
27. Li, Weiwei Aileen, Beverly Ying Lu, Luo Gu, Youngjin Choi, Jaeyun Kim, and 
David J. Mooney. “The Effect of Surface Modification of Mesoporous Silica 
Micro-Rod Scaffold on Immune Cell Activation and Infiltration.” Biomaterials 83 
(March 2016): 249–56. https://doi.org/10.1016/j.biomaterials.2016.01.026. 
 
28. Zhao, Hongjuan, Beibei Zhao, Lixia Wu, Huifang Xiao, Kaili Ding, Cuixia Zheng, 
Qingling Song, Lingling Sun, Lei Wang, and Zhenzhong Zhang. “Amplified 
Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine 
by Synergistically Modulating Tumor Microenvironment.” ACS Nano 13, no. 11 




29. Liu, Lin-Shu, Shu-Qin Liu, Steven Y Ng, Michael Froix, Tadao Ohno, and Jorge 
Heller. “Controlled Release of Interleukin-2 for Tumour Immunotherapy Using 
Alginate/Chitosan Porous Microspheres.” Journal of Controlled Release 43, no. 1 
(January 1997): 65–74. https://doi.org/10.1016/S0168-3659(96)01471-X. 
 
30. Rahimian, Sima, Marieke F. Fransen, Jan Willem Kleinovink, Maryam Amidi, 
Ferry Ossendorp, and Wim E. Hennink. “Polymeric Microparticles for Sustained 
and Local Delivery of AntiCD40 and AntiCTLA-4 in Immunotherapy of Cancer.” 
Biomaterials 61 (August 2015): 33–40. 
https://doi.org/10.1016/j.biomaterials.2015.04.043. 
 
31. Foged, Camilla, Birger Brodin, Sven Frokjaer, and Anne Sundblad. “Particle Size 
and Surface Charge Affect Particle Uptake by Human Dendritic Cells in an in Vitro 
Model.” International Journal of Pharmaceutics 298, no. 2 (July 2005): 315–22. 
https://doi.org/10.1016/j.ijpharm.2005.03.035. 
 
32. Moon, James J., Bonnie Huang, and Darrell J. Irvine. “Engineering Nano- and 
Microparticles to Tune Immunity.” Advanced Materials 24, no. 28 (July 24, 2012): 
3724–46. https://doi.org/10.1002/adma.201200446. 
 
33. Fan, Yuchen, and James Moon. “Nanoparticle Drug Delivery Systems Designed to 
Improve Cancer Vaccines and Immunotherapy.” Vaccines 3, no. 3 (August 27, 
2015): 662–85. https://doi.org/10.3390/vaccines3030662. 
 
34. Oberli, Matthias A., Andreas M. Reichmuth, J. Robert Dorkin, Michael J. Mitchell, 
Owen S. Fenton, Ana Jaklenec, Daniel G. Anderson, Robert Langer, and Daniel 
Blankschtein. “Lipid Nanoparticle Assisted MRNA Delivery for Potent Cancer 
Immunotherapy.” Nano Letters 17, no. 3 (March 8, 2017): 1326–35. 
https://doi.org/10.1021/acs.nanolett.6b03329. 
 
35. Xu, Zhenghong, Srinivas Ramishetti, Yu-Cheng Tseng, Shutao Guo, Yuhua Wang, 
and Leaf Huang. “Multifunctional Nanoparticles Co-Delivering Trp2 Peptide and 
CpG Adjuvant Induce Potent Cytotoxic T-Lymphocyte Response against 
Melanoma and Its Lung Metastasis.” Journal of Controlled Release 172, no. 1 
(November 2013): 259–65. https://doi.org/10.1016/j.jconrel.2013.08.021. 
 
36. Bobo, Daniel, Kye J. Robinson, Jiaul Islam, Kristofer J. Thurecht, and Simon R. 
Corrie. “Nanoparticle-Based Medicines: A Review of FDA-Approved Materials 
and Clinical Trials to Date.” Pharmaceutical Research 33, no. 10 (October 2016): 
2373–87. https://doi.org/10.1007/s11095-016-1958-5. 
 
37. Perrault, Steven D., Carl Walkey, Travis Jennings, Hans C. Fischer, and Warren C. 
W. Chan. “Mediating Tumor Targeting Efficiency of Nanoparticles Through 





38. Alexis, Frank, Eric Pridgen, Linda K. Molnar, and Omid C. Farokhzad. “Factors 
Affecting the Clearance and Biodistribution of Polymeric Nanoparticles.” 
Molecular Pharmaceutics 5, no. 4 (August 2008): 505–15. 
https://doi.org/10.1021/mp800051m. 
 
39. Wong, Pamela T., and Seok Ki Choi. “Mechanisms of Drug Release in 
Nanotherapeutic Delivery Systems.” Chemical Reviews 115, no. 9 (May 13, 2015): 
3388–3432. https://doi.org/10.1021/cr5004634. 
 
40. Zhang, Yuan, Na Li, Heikyung Suh, and Darrell J. Irvine. “Nanoparticle Anchoring 
Targets Immune Agonists to Tumors Enabling Anti-Cancer Immunity without 
Systemic Toxicity.” Nature Communications 9, no. 1 (December 2018): 6. 
https://doi.org/10.1038/s41467-017-02251-3. 
 
41. Kraft, John C., Jennifer P. Freeling, Ziyao. Wang, and Rodney J.Y. Ho. “Emerging 
Research and Clinical Development Trends of Liposome and Lipid Nanoparticle 
Drug Delivery Systems.” Journal of Pharmaceutical Sciences 103, no. 1 (January 
2014): 29–52. https://doi.org/10.1002/jps.23773. 
 
42. Schmid, Daniela, Chun Gwon Park, Christina A. Hartl, Nikita Subedi, Adam N. 
Cartwright, Regina Bou Puerto, Yiran Zheng, et al. “T Cell-Targeting 
Nanoparticles Focus Delivery of Immunotherapy to Improve Antitumor 
Immunity.” Nature Communications 8, no. 1 (December 2017): 1747. 
https://doi.org/10.1038/s41467-017-01830-8. 
 
43. Perez, Heidi L., Pina M. Cardarelli, Shrikant Deshpande, Sanjeev Gangwar, 
Gretchen M. Schroeder, Gregory D. Vite, and Robert M. Borzilleri. “Antibody–
Drug Conjugates: Current Status and Future Directions.” Drug Discovery Today 
19, no. 7 (July 2014): 869–81. https://doi.org/10.1016/j.drudis.2013.11.004. 
 
44. Ekladious, Iriny, Yolonda L. Colson, and Mark W. Grinstaff. “Polymer–Drug 
Conjugate Therapeutics: Advances, Insights and Prospects.” Nature Reviews Drug 
Discovery 18, no. 4 (April 2019): 273–94. https://doi.org/10.1038/s41573-018-
0005-0. 
 
45. Ringsdorf, Helmut. “Structure and Properties of Pharmacologically Active 
Polymers.” Journal of Polymer Science: Polymer Symposia 51, no. 1 (March 8, 
2007): 135–53. https://doi.org/10.1002/polc.5070510111. 
 
46. Lv, Shixian, Zhaohui Tang, Dawei Zhang, Wantong Song, Mingqiang Li, Jian Lin, 
Huaiyu Liu, and Xuesi Chen. “Well-Defined Polymer-Drug Conjugate Engineered 
with Redox and PH-Sensitive Release Mechanism for Efficient Delivery of 





47. Sievers, Eric L., and Peter D. Senter. “Antibody-Drug Conjugates in Cancer 
Therapy.” Annual Review of Medicine 64, no. 1 (January 14, 2013): 15–29. 
https://doi.org/10.1146/annurev-med-050311-201823. 
 
48. Yang, Yikun, Xiaoyin Qiao, Ruiying Huang, Haoxiang Chen, Xuelei Shi, Jian 
Wang, Weihong Tan, and Zhikai Tan. “E-Jet 3D Printed Drug Delivery Implants 
to Inhibit Growth and Metastasis of Orthotopic Breast Cancer.” Biomaterials 230 
(February 2020): 119618. https://doi.org/10.1016/j.biomaterials.2019.119618. 
 
49. Yan, Jingxuan, Yuting Miao, Huaping Tan, Tianle Zhou, Zhonghua Ling, Yong 
Chen, Xiaodong Xing, and Xiaohong Hu. “Injectable Alginate/Hydroxyapatite Gel 
Scaffold Combined with Gelatin Microspheres for Drug Delivery and Bone Tissue 
Engineering.” Materials Science and Engineering: C 63 (June 2016): 274–84. 
https://doi.org/10.1016/j.msec.2016.02.071. 
 
50. Koshy, Sandeep T., Thomas C. Ferrante, Sarah A. Lewin, and David J. Mooney. 
“Injectable, Porous, and Cell-Responsive Gelatin Cryogels.” Biomaterials 35, no. 
8 (March 2014): 2477–87. https://doi.org/10.1016/j.biomaterials.2013.11.044. 
 
51. Cheung, Alexander S., David K. Y. Zhang, Sandeep T. Koshy, and David J. 
Mooney. “Scaffolds That Mimic Antigen-Presenting Cells Enable Ex Vivo 
Expansion of Primary T Cells.” Nature Biotechnology 36, no. 2 (February 2018): 
160–69. https://doi.org/10.1038/nbt.4047. 
 
52. Subia, B., J. Kundu, and S. C. “Biomaterial Scaffold Fabrication Techniques for 
Potential Tissue Engineering Applications.” In Tissue Engineering, edited by 
Daniel Eberli. InTech, 2010. https://doi.org/10.5772/8581. 
 
53. De Temmerman, Marie-Luce, Joanna Rejman, Jo Demeester, Darrell J. Irvine, 
Bruno Gander, and Stefaan C. De Smedt. “Particulate Vaccines: On the Quest for 
Optimal Delivery and Immune Response.” Drug Discovery Today 16, no. 13 (July 
1, 2011): 569–82. https://doi.org/10.1016/j.drudis.2011.04.006. 
 
54. Davoodi, Pooya, Wei Cheng Ng, Madapusi P. Srinivasan, and Chi-Hwa Wang. 
“Codelivery of Anti-Cancer Agents via Double-Walled Polymeric 
Microparticles/Injectable Hydrogel: A Promising Approach for Treatment of 
Triple Negative Breast Cancer.” Biotechnology and Bioengineering 114, no. 12 
(2017): 2931–46. https://doi.org/10.1002/bit.26406. 
 
55. Hamid, Omid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, 
Richard Kefford, Jedd D. Wolchok, et al. “Safety and Tumor Responses with 
Lambrolizumab (Anti–PD-1) in Melanoma.” New England Journal of Medicine 
369, no. 2 (July 11, 2013): 134–44. https://doi.org/10.1056/NEJMoa1305133. 
 
56. Topalian, Suzanne L., F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David 
C. Smith, David F. McDermott, John D. Powderly, et al. “Safety, Activity, and 
 61 
 
Immune Correlates of Anti–PD-1 Antibody in Cancer.” New England Journal of 
Medicine 366, no. 26 (June 28, 2012): 2443–54. 
https://doi.org/10.1056/NEJMoa1200690. 
 
57. Hussein, M., J. R. Berenson, R. Niesvizky, N. Munshi, J. Matous, R. Sobecks, K. 
Harrop, J. G. Drachman, and N. Whiting. “A Phase I Multidose Study of 
Dacetuzumab (SGN-40; Humanized Anti-CD40 Monoclonal Antibody) in Patients 
with Multiple Myeloma.” Haematologica 95, no. 5 (May 1, 2010): 845–48. 
https://doi.org/10.3324/haematol.2009.008003. 
 
58. Vermonden, Tina, Roberta Censi, and Wim E. Hennink. “Hydrogels for Protein 
Delivery.” Chemical Reviews 112, no. 5 (May 9, 2012): 2853–88. 
https://doi.org/10.1021/cr200157d. 
 
59. Pisal, Dipak S., Matthew P. Kosloski, and Sathy V. Balu‐Iyer. “Delivery of 
Therapeutic Proteins.” Journal of Pharmaceutical Sciences 99, no. 6 (2010): 2557–
75. https://doi.org/10.1002/jps.22054. 
 
60. Wilhelm, Stefan, Anthony J. Tavares, Qin Dai, Seiichi Ohta, Julie Audet, Harold 
F. Dvorak, and Warren C. W. Chan. “Analysis of Nanoparticle Delivery to 
Tumours.” Nature Reviews Materials 1, no. 5 (May 2016): 16014. 
https://doi.org/10.1038/natrevmats.2016.14. 
 
61. Wang, Andrew Z., Robert Langer, and Omid C. Farokhzad. “Nanoparticle Delivery 
of Cancer Drugs.” Annual Review of Medicine 63, no. 1 (February 18, 2012): 185–
98. https://doi.org/10.1146/annurev-med-040210-162544. 
 
62. Korangath, Preethi, James D. Barnett, Anirudh Sharma, Elizabeth T. Henderson, 
Jacqueline Stewart, Shu-Han Yu, Sri Kamal Kandala, et al. “Nanoparticle 
Interactions with Immune Cells Dominate Tumor Retention and Induce T Cell–
Mediated Tumor Suppression in Models of Breast Cancer.” Science Advances 6, 
no. 13 (March 2020): eaay1601. https://doi.org/10.1126/sciadv.aay1601. 
 
63. Miller, Miles A., Suresh Gadde, Christina Pfirschke, Camilla Engblom, Melissa M. 
Sprachman, Rainer H. Kohler, Katherine S. Yang, et al. “Predicting Therapeutic 
Nanomedicine Efficacy Using a Companion Magnetic Resonance Imaging 
Nanoparticle.” Science Translational Medicine 7, no. 314 (November 18, 2015): 
314ra183-314ra183. https://doi.org/10.1126/scitranslmed.aac6522. 
 
64. Graciotti, Michele, Cristiana Berti, Harm-Anton Klok, and Lana Kandalaft. “The 
Era of Bioengineering: How Will This Affect the next Generation of Cancer 
Immunotherapy?” Journal of Translational Medicine 15, no. 1 (December 2017): 
142. https://doi.org/10.1186/s12967-017-1244-2. 
 
65. Manolova, Vania, Anna Flace, Monika Bauer, Katrin Schwarz, Philippe Saudan, 
and Martin F. Bachmann. “Nanoparticles Target Distinct Dendritic Cell 
 62 
 
Populations According to Their Size.” European Journal of Immunology 38, no. 5 
(2008): 1404–13. https://doi.org/10.1002/eji.200737984. 
 
66. Li, Jun, Yang Yang, and Leaf Huang. “Calcium Phosphate Nanoparticles with an 
Asymmetric Lipid Bilayer Coating for SiRNA Delivery to the Tumor.” Journal of 
Controlled Release 158, no. 1 (February 2012): 108–14. 
https://doi.org/10.1016/j.jconrel.2011.10.020. 
 
67. Hickey, John W., Fernando P. Vicente, Gregory P. Howard, Hai-Quan Mao, and 
Jonathan P. Schneck. “Biologically Inspired Design of Nanoparticle Artificial 
Antigen-Presenting Cells for Immunomodulation.” Nano Letters 17, no. 11 
(November 8, 2017): 7045–54. https://doi.org/10.1021/acs.nanolett.7b03734. 
 
68. Yih, T. C., and M. Al‐Fandi. “Engineered Nanoparticles as Precise Drug Delivery 
Systems.” Journal of Cellular Biochemistry 97, no. 6 (2006): 1184–90. 
https://doi.org/10.1002/jcb.20796. 
 
69. Wilczewska, Agnieszka Z., Katarzyna Niemirowicz, Karolina H. Markiewicz, and 
Halina Car. "Nanoparticles as Drug Delivery Systems." Pharmacological Reports 
64, no. 5 (2012): 1020. 
 
70. Shi, Gao-Na, Chuang-Nian Zhang, Rong Xu, Jin-Feng Niu, Hui-Juan Song, Xiu-
Yuan Zhang, Wei-Wei Wang, et al. “Enhanced Antitumor Immunity by Targeting 
Dendritic Cells with Tumor Cell Lysate-Loaded Chitosan Nanoparticles Vaccine.” 
Biomaterials 113 (January 2017): 191–202. 
https://doi.org/10.1016/j.biomaterials.2016.10.047. 
 
71. Reichert, Janice M, Clark J Rosensweig, Laura B Faden, and Matthew C Dewitz. 
“Monoclonal Antibody Successes in the Clinic.” Nature Biotechnology 23, no. 9 
(September 2005): 1073–78. https://doi.org/10.1038/nbt0905-1073. 
 
72. Senter, Peter D. “Potent Antibody Drug Conjugates for Cancer Therapy.” Current 
Opinion in Chemical Biology 13, no. 3 (June 2009): 235–44. 
https://doi.org/10.1016/j.cbpa.2009.03.023. 
 
73. Teicher, B. A., and R. V. J. Chari. “Antibody Conjugate Therapeutics: Challenges 
and Potential.” Clinical Cancer Research 17, no. 20 (October 15, 2011): 6389–97. 
https://doi.org/10.1158/1078-0432.CCR-11-1417. 
 
74. Caliceti, P. “Pharmacokinetic and Biodistribution Properties of Poly(Ethylene 
Glycol)–Protein Conjugates.” Advanced Drug Delivery Reviews 55, no. 10 
(September 26, 2003): 1261–77. https://doi.org/10.1016/S0169-409X(03)00108-X. 
 
75. Turecek, Peter L., Mary J. Bossard, Freddy Schoetens, and Inge A. Ivens. 
“PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical 
 63 
 
Safety Information of Approved Drugs.” Journal of Pharmaceutical Sciences 105, 
no. 2 (February 2016): 460–75. https://doi.org/10.1016/j.xphs.2015.11.015. 
 
76. Andorko, James I., Krystina L. Hess, Kevin G. Pineault, and Christopher M. Jewell. 
“Intrinsic Immunogenicity of Rapidly-Degradable Polymers Evolves during 
Degradation.” Acta Biomaterialia 32 (March 2016): 24–34. 
https://doi.org/10.1016/j.actbio.2015.12.026. 
 
77. Pickup, Michael, Sergey Novitskiy, and Harold L. Moses. 2013. “The Roles of 
TGFβ in the Tumour Microenvironment.” Nature Reviews Cancer 13 (11): 788–
99. doi:10.1038/nrc3603. 
 
78. Gros, Alena, Paul F. Robbins, Xin Yao, Yong F. Li, Simon Turcotte, Eric Tran, 
John R. Wunderlich, et al. “PD-1 Identifies the Patient-Specific CD8+ Tumor-
Reactive Repertoire Infiltrating Human Tumors.” Journal of Clinical Investigation 
124, no. 5 (May 1, 2014): 2246–59. https://doi.org/10.1172/JCI73639. 
 
79. Lengyel, Miléna, Nikolett Kállai-Szabó, Vince Antal, András József Laki, and 
István Antal. “Microparticles, Microspheres, and Microcapsules for Advanced 
Drug Delivery.” Scientia Pharmaceutica 87, no. 3 (August 9, 2019): 20. 
https://doi.org/10.3390/scipharm87030020. 
 
 
